Followers | 20 |
Posts | 5349 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Monday, July 31, 2017 6:02:33 PM
In 2011 the presentation they were looking at a quick switch of 4 million prescriptions from physicians already prescribing off label and compounded testosterone. Assuming $500 /prescription (price will most likely be higher) that produces $2 billion in revenue out of the gates.
Using the same $500 drug price, they expected to grow this to $4.5 billion to treat HSDD once an FDA approved drug makes it to market.
The CV risk reduction sales most likely targeting patients with Hypertension and Dyslipidemia will most likely produce a much greater sales than the HSDD market. But for the sake of argument lets assume peak sales of $10 billion.
For an approved product, ANI could expect a deal in the vicinity of 2.5 X peak sales. However the drug is not approved and most likely will be taken the rest of the way by the partner. The trials were under and FDA SPA. Therefore they would have an increase chance of approval. However it is not a guarantee. Price will also depend on how they attribute the percentage of value between the two companies.
For the sake of argument let's assume that they agreed to a 50/50 assertion of value for work done.
$10 billion in peak sales X 50% = $5 billion X2.5 =$12 Billion
Therefore ANI may base the value for their share of the drug at $12 billion for an approved drug. However it is not approved though it has been greatly de-risked and may be looking at a 30% discount. (Note:They could still get market exclusivity for 5 years and do have the TRT patents to 2031). The discount could be more or less given the level of risk of not getting approved.
Therefore $12 Billion- 30% = $8.75 billion /approx 14 million shares once the Sr notes are coverted. PPS could be in the $625 range.
Personally, I believe global sales will eventually surpass $10 billion. If they peak sales are projected to compete with Humira Peak sales in
the PPS in a deal would be closer to $1125.
Recent ANIP News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:09:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:55:18 AM
- ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • GlobeNewswire Inc. • 05/10/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 04/18/2024 08:05:00 PM
- ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension • GlobeNewswire Inc. • 04/09/2024 10:50:00 AM
- ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium • GlobeNewswire Inc. • 04/03/2024 10:50:00 AM
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP • GlobeNewswire Inc. • 03/27/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:25:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:59:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:26:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:42:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:21:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:16:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:11:59 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:58:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:31:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:24:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:18:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:12:45 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM